| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Nautilus Biotechnology, Inc.$2
-0.2 (-8.81%)
D 28Pipeline Score Diagnostics · Clinical
Market Cap
322.78 M
EPS
-0.45
P/E Ratio
-
Value Trade
969.62 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
9.71 M
Operating CF
-13.10 M
Total Assets
177.78 M
Total Liabilities
33.36 M
Equity
144.41 M
D/E Ratio
12,345
-1.93 %
Week
-9.93 %
1 Month
-12.11 %
3 Month
15.98 %
6 Month
-77.89 %
5 Year
-77.89 %
All Time
Cash Data
Cash Position
95.87 M
Monthly Burn
4.37 M
Runway
20.1 mo
Burn Trend
StableSEC Filing
Apr 28, 2026
Overview
Volume
7.70 M
52 Week Range
0.62 - 4.31
% held by Insiders
52.95 %
% held by Institutions
27.57 %
Enterprise Value
255.78 M
Total Shares
127.12 M
Short %
1.32 %
Float Shares
41.06 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D28
Pipeline Score $30M
Pipeline ValueValuation Signal
1
Drugs Scored0.1x
rNPV / MCap Top 31%
Micro Cap (rank 625 of 905)
Percentile RankNautilus Biotechnology, Inc. faces pipeline headwinds (28/100), with $140M risk-adjusted pipeline value, led by MDMA in Post-Traumatic Stress Disorder (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDMA Small molecule | Post-Traumatic Stress Disorder | Phase 2 | NCT05455996 | 27% | $140M | NOT YET_RECRUITING | 30 | - | - | Jun 1, 2028 | - | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in NAUT
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
NAUT
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
NAUT
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
NAUT
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
NAUT Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
NAUT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
NAUTNautilus Biotechnology Reports First Quarter 2026 Financial Results
Nautilus Biotechnology reported its Q1 2026 financial results, highlighting the initiation of an Early Access Program for its Tau proteoform assay. The company saw a decrease in operating expenses and appointed a new VP of Global Sales to enhance customer engagement. Despite a net loss, Nautilus is making strides toward commercialization and platform validation.
Read more →NAUTNautilus Biotechnology to Announce First Quarter 2026 Financial Results on April 28, 2026
Nautilus Biotechnology, Inc. will announce its financial results for Q1 2026 on April 28, 2026. The announcement will be made before market open, followed by a conference call to discuss the results and future outlook. The company focuses on advancing proteomics technology to enhance human health.
Read more →NAUTNautilus Biotechnology to Participate in the Investor Summit Group Virtual Conference
Nautilus Biotechnology, Inc. will participate in the Investor Summit Group Virtual Conference on March 25, 2026. The presentation will be accessible live and archived on their website. Nautilus is focused on developing a technology platform for protein analysis, aiming to advance the field of proteomics.
Read more →NAUTNautilus Biotechnology Announces Baylor College of Medicine as First Early Access Program Customer for Voyager Platform
Nautilus Biotechnology has announced Baylor College of Medicine as the inaugural customer for its Voyager Platform through an Early Access Program. The collaboration, supported by the NIH, focuses on leveraging Nautilus' unique single-molecule proteomics method to enhance cancer research by identifying aberrant protein isoforms. This initiative aims to create a comprehensive computational toolkit for better detection of protein isoforms and biomarker analysis. The project represents a significant step towards integrating proteomic data with genomic studies in cancer biology.
Read more →NAUTNautilus Biotechnology Appoints Proteomics Commercial Leader Amber Faust as Vice President of Sales
Nautilus Biotechnology has appointed Amber Faust as Vice President of Sales to lead the commercialization of its Voyager™ Platform. Faust, with nearly two decades of experience in proteomics, will oversee the launch and market introduction of the platform, which aims to enhance single-molecule protein analysis. The company is progressing towards commercialization with its Iterative Mapping Early Access Program and aims for a commercial launch in late 2026.
Read more →NAUTNautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2025 Financial Results
Nautilus Biotechnology reported its financial results for Q4 and fiscal year 2025, highlighting a decrease in operating expenses and a net loss reduction. The company is focused on expanding its Early Access Program and aims for commercialization by late 2026. Despite a strong cash position, it anticipates no significant revenue in 2026.
Read more →NAUTNautilus Biotechnology Unveils Voyager Platform, Enabling Single-Molecule Iterative Mapping, at US HUPO 2026
Nautilus Biotechnology unveiled its Voyager Platform at the US HUPO 2026 conference, designed for single-molecule proteome analysis. The platform can measure up to 10 billion intact proteins simultaneously, promising to advance proteomics research. An Early Access Program is now open for researchers, with commercial launch anticipated in late 2026.
Read more →NAUTNautilus Biotechnology to Participate in the TD Cowen 46th Annual Health Care Conference
Nautilus Biotechnology, Inc. has announced its participation in the TD Cowen 46th Annual Health Care Conference, scheduled for March 2, 2026. During the event, Nautilus management will engage in a fireside chat, which can be accessed live and archived on the company's website. Nautilus is focused on revolutionizing the field of proteomics through its innovative platform technology, aiming to enhance understanding and access to the proteome.
Read more →NAUTNautilus Biotechnology to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Nautilus Biotechnology, Inc. announced it will release its financial results for Q4 and the full year 2025 on February 26, 2026. The company will hold a conference call to discuss these results and its business outlook. This event highlights Nautilus's ongoing developments in the field of proteomics.
Read more →NAUTNautilus Biotechnology and Weill Cornell Medicine-Qatar Collaborate with The Michael J. Fox Foundation to Advance Single-Molecule Proteomics Research in Parkinson’s Disease
Nautilus Biotechnology has partnered with Weill Cornell Medicine-Qatar and The Michael J. Fox Foundation to advance research on alpha-synuclein in Parkinson's disease. The collaboration, supported by a $1.6 million grant, aims to develop a single-molecule assay to measure various proteoforms of alpha-synuclein. This research could improve understanding of the disease and enhance biomarker development for clinical trials.
Read more →NAUTNautilus Biotechnology Launches Early Access Program for Novel Single-Molecule Proteomics Platform, Starting with Tau Proteoforms Assay
Nautilus Biotechnology has launched an Early Access Program for its novel proteomics platform, starting with a tau proteoforms assay aimed at Alzheimer’s research. This initiative allows selected researchers to utilize Nautilus' Iterative Mapping method, which provides high-resolution insights into protein variations. The company emphasizes that its platform delivers unique capabilities compared to traditional proteomics methods. Initial validation and positive feedback from research partners demonstrate the platform's potential impact on advancing neurodegenerative biology studies.
Read more →NAUTNautilus Biotechnology Reports Successful Installation and Testing of its First Field Evaluation Unit at the Buck Institute for Research on Aging
Nautilus Biotechnology has successfully installed its first external field evaluation unit at the Buck Institute for Research on Aging. This milestone allows independent labs to access Nautilus' single-molecule proteomics platform, generating reproducible data on tau proteoforms related to neurodegenerative diseases. The collaboration aims to advance research on Alzheimer's disease, with initial findings set to be presented at the 2025 HUPO World Congress.
Read more →NAUTNautilus Biotechnology Reports Third Quarter 2025 Financial Results
Nautilus Biotechnology reported its financial results for Q3 2025, highlighting a 19% reduction in operating expenses and a net loss of $13.6 million. The company is focused on launching its early access program for Tau proteoforms in 2026, aiming for full commercialization by late 2026. Nautilus currently holds $168.5 million in cash and investments.
Read more →NAUTNautilus Biotechnology to Announce Third Quarter 2025 Financial Results on October 28, 2025
Nautilus Biotechnology, Inc. is set to announce its financial results for the third quarter of 2025 before the market opens on October 28, 2025. The announcement will be followed by a conference call at 5:30 a.m. Pacific Time, where management will discuss the results and future outlook. Nautilus focuses on developing a platform technology aimed at unlocking the complexity of the proteome, which is integral to advancements in health and medicine.
Read more →NAUTNautilus Biotechnology to Participate in Upcoming September Investor Conferences
Nautilus Biotechnology, Inc. announced its participation in upcoming investor conferences. The company, known for its innovative single-molecule protein analysis platform, aims to enhance access to proteomics. Interested parties can access live and archived webcasts of the presentations on their website. Nautilus is focused on advancing human health through its technology.
Read more →NAUTNautilus Biotechnology Reports Second Quarter 2025 Financial Results SEATTLE, WA
Nautilus Biotechnology reported its financial results for the second quarter of 2025, highlighting significant advancements in its proteome analysis platform. The company experienced a reduction in operating expenses and a smaller net loss compared to the previous year. Key milestones included the publication of a scientific manuscript featuring novel data and new collaborations with research institutes to study Tau proteoforms in Alzheimer's disease models. Despite these achievements, Nautilus continues to face challenges with its platform's commercialization and further development needs.
Read more →NAUTNautilus Biotechnology Announces Agreement with the Allen Institute, Further Validating its Approach to Single-Molecule Proteomics
Nautilus Biotechnology has partnered with the Allen Institute to explore the role of tau protein in Alzheimer's disease using its single-molecule proteomics method. This collaboration aims to identify and characterize tau proteoforms, which could lead to breakthroughs in diagnostics and treatment. The agreement highlights the significance of Nautilus's Iterative Mapping approach in advancing proteomic research.
Read more →NAUTNautilus Biotechnology to Announce Second Quarter 2025 Financial Results on July 31, 2025
Nautilus Biotechnology, Inc. announced that it will release its financial results for the second quarter of 2025 on July 31, 2025, before the market opens. The company plans to host a webcast conference call to discuss these results along with business developments and their future outlook. Nautilus is known for its single-molecule protein analysis platform aimed at advancing proteomics for improved health outcomes.
Read more →NAUTNautilus Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
Nautilus Biotechnology, Inc. will participate in the Goldman Sachs 46th Annual Global Healthcare Conference on June 10, 2025. The event will feature a fireside chat with the company's management, which will be accessible via a live and archived webcast. Nautilus aims to innovate in the field of proteomics through its unique platform technology.
Read more →NAUTNautilus Biotechnology Reports First Quarter 2025 Financial Results SEATTLE, WA
Nautilus Biotechnology, Inc. reported its financial results for Q1 2025, showing a net loss of $16.6 million, an improvement from $18.7 million during the same quarter last year. Operating expenses decreased to $18.8 million, reflecting the company's focus on cost optimization. The company is progressing with its Tau proteoform assay, aiming to revolutionize research into Alzheimer's disease. Nautilus emphasizes that the product is not yet commercially available and further validation is required before launch.
Read more →NAUTNautilus Biotechnology to Announce First Quarter 2025 Financial Results on April 29, 2025
Nautilus Biotechnology, Inc. has announced that it will report its financial results for the first quarter of 2025 on April 29, 2025, before market open. The company will also hold a conference call to discuss these results along with business developments and its outlook. This announcement is part of Nautilus's ongoing efforts to advance its single-molecule proteome analysis platform and its mission to enable advancements in human health and medicine.
Read more →NAUTNautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2024 Financial Results SEATTLE, WA
Nautilus Biotechnology reported its financial results for Q4 and the fiscal year 2024, showing stable operating expenses but a notable increase in net loss. The company anticipates launching its proteome analysis platform in late 2026 while managing expenses and reducing headcount to align resources more effectively. Despite innovations and advancements, the overall financial performance indicates challenges, particularly with higher losses compared to the previous year.
Read more →NAUTNautilus Biotechnology to Participate in the TD Cowen 45th Annual Healthcare Conference
Nautilus Biotechnology, Inc. is set to participate in the TD Cowen 45th Annual Healthcare Conference. Scheduled for March 3, 2025, management will take part in a fireside chat, which can be accessed through the company website. The participation highlights Nautilus' advancements in the field of proteomics and its commitment to improving human health.
Read more →NAUTNautilus Biotechnology to Announce Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
Nautilus Biotechnology, Inc. plans to announce its fourth-quarter and full-year financial results for 2024 on February 27, 2025, before the market opens. The announcement will be accompanied by a conference call scheduled for 5:30 a.m. Pacific Time, where management will discuss results and future outlook. Nautilus focuses on revolutionizing proteomics through its unique single molecule protein analysis platform.
Read more →NAUTNautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with the Academy for Radiology and Biomedical Imaging Research’s Distinguished Investigator Award
Nautilus Biotechnology announced that co-founder and Chief Scientist Parag Mallick, Ph.D., received the prestigious 2024 Distinguished Investigator Award by the Academy for Radiology and Biomedical Imaging Research. This award honors his significant contributions to imaging research, including leadership and high-impact publications. Dr. Mallick will be inducted into the Academy's Council of Distinguished Investigators during the Radiological Society of North America's Annual Meeting in December 2024.
Read more →NAUTNautilus Biotechnology to Participate in the Inaugural Guggenheim Healthcare Conference
Nautilus Biotechnology, Inc. announced its participation in the inaugural Guggenheim Healthcare Conference, scheduled for November 13, 2024. The company's management will engage in a fireside chat to discuss their pioneering single-molecule protein analysis platform. Interested parties can access a live and archived webcast through Nautilus's website. This event represents a strategic opportunity for Nautilus to increase visibility and support for its innovation in proteomics.
Read more →NAUTNautilus Biotechnology Reports Third Quarter 2024 Financial Results SEATTLE, WA
Nautilus Biotechnology, Inc. has reported its financial results for the third quarter of 2024, showing a net loss of $16.4 million, slightly higher than the previous year. The company's operating expenses remained stable at $19.1 million, although increased personnel costs were noted. CEO Sujal Patel highlighted positive feedback from researchers regarding their single-molecule proteome analysis platform, which is still in development and not yet commercially available. Nautilus maintains a strong cash position of $221.2 million, supporting its ongoing research and platform development efforts.
Read more →NAUTNautilus Biotechnology to Announce Third Quarter 2024 Financial Results on October 29, 2024
Nautilus Biotechnology, Inc. is set to announce its financial results for the third quarter of 2024 on October 29, 2024. The announcement will be followed by a conference call to discuss the results, business developments, and future outlook. Investors can listen to the live webcast on the company's website. Nautilus focuses on creating a platform for protein analysis to advance healthcare and medicine.
Read more →NAUTNautilus Biotechnology Appoints Mass Spectrometry Leader Ken Suzuki as Chief Marketing Officer
Nautilus Biotechnology has appointed Ken Suzuki as its Chief Marketing Officer, bringing in over 25 years of experience in product and marketing roles, predominantly at Agilent Technologies. His expertise is expected to enhance Nautilus' efforts in bringing their Proteome Analysis Platform to market, which aims to advance the field of proteomics. CEO Sujal Patel emphasized the strategic importance of Suzuki's appointment as the company prepares to innovate in protein analysis technologies. However, Nautilus still faces challenges, including the need for product validation and potential delays in commercial availability.
Read more →NAUTNautilus Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Nautilus Biotechnology, Inc. announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference set for September 4, 2024, in New York. Management will engage in a fireside chat, which highlights the company's growing presence in the healthcare sector. The event indicates Nautilus's efforts to enhance investor relations and promote its innovative proteome analysis platform. Interested individuals can access a live and archived webcast of the presentation on the company's website.
Read more →NAUTNautilus Biotechnology Reports Second Quarter 2024 Financial Results SEATTLE, WA
Nautilus Biotechnology reported its second quarter 2024 financial results, demonstrating progress on development goals for its unique proteome analysis platform. The company experienced a net loss of $18 million, up from $15.8 million year-over-year, while operating expenses increased by 9%. Despite the losses, Nautilus holds substantial cash reserves which it can leverage for development and operational support.
Read more →NAUTNautilus Biotechnology to Announce Second Quarter 2024 Financial Results on July 30, 2024
Nautilus Biotechnology, Inc. has announced that it will release its financial results for the second quarter of 2024 on July 30, 2024, before the markets open. The company will hold a conference call to discuss these results, along with updates on business developments and its outlook. This session will be available to investors via a webcast on their website. Nautilus is focused on advancing the proteomics field to enhance access to crucial biological information.
Read more →NAUTNautilus Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Nautilus Biotechnology, Inc. will participate in the Goldman Sachs 45th Annual Global Healthcare Conference, scheduled for June 10, 2024. The company's management will take part in a fireside chat at 8:40 a.m. Eastern Time. This event allows Nautilus to present its innovative protein analysis platform to a wider audience and demonstrates its commitment to the field of proteomics. Interested parties can access the presentation via Nautilus' website.
Read more →NAUTNautilus Biotechnology Reports First Quarter 2024 Financial Results SEATTLE, WA
Nautilus Biotechnology, Inc. reported its financial results for the first quarter of 2024, indicating continued development progress on its proteomics platform. The company's operating expenses rose to $21.6 million, primarily due to increased headcount. Despite facing a larger net loss of $18.7 million, Nautilus holds $247.7 million in cash equivalents and investments. CEO Sujal Patel expressed confidence in the team's ability to establish a new standard for proteomic analysis while acknowledging the challenges ahead. A conference call is scheduled to further discuss these developments.
Read more →NAUTNautilus Biotechnology to Announce First Quarter 2024 Financial Results on April 30, 2024
Nautilus Biotechnology, Inc. announced it will report its first quarter 2024 financial results before the market opens on April 30, 2024. The company will host a conference call on the same day at 5:30 a.m. Pacific Time to discuss the results along with business developments and future outlook. This is part of Nautilus's mission to advance the field of proteomics through its innovative platform technology.
Read more →NAUTNautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2023 Financial Results SEATTLE, WA
Nautilus Biotechnology reported its fourth quarter and fiscal year 2023 financial results, highlighting significant progress on its single molecule proteome analysis platform. The company experienced an increase in operating expenses and a higher net loss compared to the previous year. Despite these financial challenges, Nautilus maintains a robust cash position projected to sustain operations through 2026 and aims to launch its platform in 2025. CEO Sujal Patel emphasized the importance of the company's advancements in the proteomics field.
Read more →NAUTNautilus Biotechnology to Announce Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
Nautilus Biotechnology, Inc. announced that it will report its financial results for the fourth quarter and full year of 2023 on February 28, 2024. The announcement includes plans for a conference call to discuss these results and provide insights into the company's business developments and outlook. This event emphasizes Nautilus's ongoing commitment to transforming proteomics and advancing human health.
Read more →NAUTNautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with US HUPO Computational Proteomics Award
Nautilus Biotechnology announced that co-founder and Chief Scientist Parag Mallick, Ph.D., has been honored with the 2024 Gilbert S. Omenn Computational Proteomics Award by the US Human Proteome Organization. This award acknowledges his substantial contributions to bioinformatics and computational methods utilized in the proteomics community. Dr. Mallick will accept the award and present a lecture at the upcoming US HUPO conference in Portland, Oregon, scheduled for March 2024. The recognition highlights Nautilus' commitment to advancing the field of proteomics.
Read more →NAUTNautilus Biotechnology Appoints Martin Huber, Ph.D., as Vice President of Biochemistry and Flow Cell Development
Nautilus Biotechnology has appointed Martin Huber, Ph.D., as Vice President of Biochemistry and Flow Cell Development, expanding its R&D leadership team. Dr. Huber has over 20 years of experience in biotechnology startups and was previously the CEO of Quantapore. His expertise is expected to enhance Nautilus's capabilities as they prepare to launch their innovative single-molecule protein analysis platform next year. This strategic appointment aims to broaden the skillset within the company ahead of significant product developments.
Read more →NAUTNautilus Biotechnology Reports Third Quarter 2023 Financial Results SEATTLE, WA
Nautilus Biotechnology, Inc. reported its financial results for the third quarter of 2023, showing a net loss of $15.9 million compared to $14.1 million the previous year. The company is focused on preparing its single molecule proteome analysis platform for commercial launch next year and has noted a significant increase in operating expenses. Despite the losses, CEO Sujal Patel conveyed optimism regarding Nautilus's position in the growing proteomics sector, emphasizing ongoing commitments to financial discipline and product development.
Read more →NAUTNautilus Biotechnology to Announce Third Quarter Financial Results on October 31, 2023
Nautilus Biotechnology, Inc. has announced that it will report its third-quarter financial results on October 31, 2023, before the market opens. Alongside the results, the company will host a conference call to discuss its business developments and future outlook. The call is scheduled for 5:30 a.m. Pacific Time and will be accessible via the company's website, showcasing its commitment to investor engagement.
Read more →NAUTNautilus Biotechnology to Participate in Upcoming August Investor Conferences
Nautilus Biotechnology, Inc. (NASDAQ: NAUT) has announced its participation in several upcoming investor conferences, including the Canaccord 43rd Annual Growth Conference and the UBS MedTech, Tools and Genomics Summit 2023. Management is set to participate in a panel discussion on the future of proteomics and will hold one-on-one meetings with investors. This involvement underscores the company's commitment to advancing its innovative protein analysis platform and its efforts to engage with the investment community.
Read more →NAUTNautilus Biotechnology Reports Second Quarter 2023 Financial Results SEATTLE, WA
Nautilus Biotechnology, Inc. reported its financial results for the second quarter of 2023, indicating solid progress towards launching its single molecule proteome analysis platform. The company's CEO highlighted the integration of platform elements essential for future market launch, expressing confidence in their financial management that supports operations through 2026. However, Nautilus also reported a 23% increase in operating expenses compared to the previous year, and a net loss of $15.8 million, which is higher than the previous year’s loss.
Read more →NAUTNautilus Biotechnology to Announce Second Quarter Financial Results on August 2, 2023
Nautilus Biotechnology, Inc. has announced it will report its second-quarter financial results on August 2, 2023, before the market opens. The company plans to host a conference call at 5:30 a.m. PT to discuss these results alongside business developments and future outlook. Nautilus focuses on revolutionizing proteomics through its innovative protein analysis platform.
Read more →NAUTNautilus Biotechnology to Participate in Upcoming June Investor Conferences
Nautilus Biotechnology, Inc. announced its participation in two investor conferences in June 2023. The company will host a fireside chat at the Jefferies 2023 Healthcare Conference on June 8th and another at the Goldman Sachs 44th Annual Global Healthcare Conference on June 12th. These presentations aim to highlight Nautilus' advancements in single-molecule protein analysis and the potential impact on human health. Interested participants can access the webcasts through the company's website.
Read more →NAUTNautilus Biotechnology Reports First Quarter 2023 Financial Results SEATTLE, WA
Nautilus Biotechnology reported its financial results for the first quarter of 2023, showing a net loss of $15.0 million, down from $15.8 million in the same period last year. The company achieved significant milestones, including the granting of 4 new U.S. patents and the announcement of winners in its First Access Challenge, which engages researchers in various scientific areas. The increase in operating expenses, however, raises concerns about the company’s financial management as it progresses towards its platform launch planned for mid-2024.
Read more →NAUTNautilus Biotechnology to Announce First Quarter Financial Results on May 2, 2023
Nautilus Biotechnology, Inc. has announced that it will report its first quarter financial results on May 2, 2023. A corresponding conference call will be held to discuss the results and business developments. This reflects the company's commitment to transparency and ongoing engagement with its investors. Nautilus is focused on advancing protein analysis technology and its role in proteomics.
Read more →NAUTNautilus Biotechnology to Participate in B. Riley Securities’ Disruptive Biotech Enabling Technologies – Proteomics, Virtual Conference
Nautilus Biotechnology, Inc. has announced its participation in the B. Riley Securities' Disruptive Biotech Enabling Technologies – Proteomics Virtual Conference. The company will host a fireside chat on April 6th to discuss its innovations in protein analysis. Nautilus aims to transform proteomics and advance human health through its platform technology. The event is expected to enhance engagement with investors and stakeholders in the biotechnology space.
Read more →NAUTNautilus Biotechnology Announces “First Access Challenge” Winners
Nautilus Biotechnology has announced the winners of its First Access Challenge, selecting three research proposals aimed at advancing proteomic analysis. The winning projects, announced at the US HUPO 2023 Conference, cover areas such as therapeutics for acute kidney injuries, the pathology of pulmonary fibrosis, and cancer therapies for glioma. The winners will gain early access to Nautilus' single-molecule proteomic data and work collaboratively with Nautilus scientists. This initiative is expected to spur significant developments in biomedical research.
Read more →NAUTNautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2022 Financial Results SEATTLE, WA
Nautilus Biotechnology reported its fourth quarter and fiscal year 2022 financial results, revealing a strategic partnership with TGen to study protein targets in DIPG. Despite increasing operating expenses to support product development and a net loss of $57.9 million for the year, the company reported decreased spending from the previous quarter and substantial cash reserves. Nautilus also presented significant scientific findings at industry conferences and expanded its footprint by opening a new office in San Diego. The CEO expressed optimism about future developments and the upcoming commercial launch.
Read more →NAUTNautilus Biotechnology to Participate in the 43rd Annual Cowen Health Care Conference
Nautilus Biotechnology, Inc. announced its participation in the 43rd Annual Cowen Health Care Conference, scheduled for March 6th. The event will include a fireside chat featuring management, which can be accessed through a live webcast on the company's website. Nautilus is recognized for its pioneering work in single-molecule protein analysis, aiming to advance the field of proteomics. The event presents an opportunity for stakeholders to gain insights into the company's developments and mission.
Read more →NAUTNautilus Biotechnology to Announce Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
Nautilus Biotechnology, Inc. is set to announce its financial results for the fourth quarter and full year of 2022 on February 23, 2023. The announcement will include a conference call at 5:30 a.m. Pacific Time, where management will discuss the results and the company's outlook. Nautilus is focused on developing a platform technology for protein analysis, aimed at advancing the field of proteomics.
Read more →NAUTNautilus Biotechnology Expands to San Diego
Nautilus Biotechnology has announced the opening of a new office in San Diego, California, as part of its expansion strategy. The 7,000-square-foot facility will accommodate various departments, including engineering and bioinformatics, enhancing the company's capacity for research and development. This move is intended to leverage San Diego's biotech community and further Nautilus's mission to advance the understanding of the human proteome. The company is also involved in collaborations with notable organizations such as TGen and Genentech.
Read more →NAUTNautilus Biotechnology Partners with the Translational Genomics Research Institute (TGen) to Investigate Applications of Single-Molecule Proteomic Analysis in Diffuse Intrinsic Pontine Glioma (DIPG)
Nautilus Biotechnology has announced a partnership with the Translational Genomics Research Institute (TGen) to explore the applications of its single-molecule proteomics platform in the study of diffuse intrinsic pontine glioma (DIPG), a rare childhood brain cancer. The collaboration aims to understand the epigenetic mechanisms of DIPG by investigating specific protein targets at the single-molecule level. While this partnership represents a step forward for Nautilus, their product platform remains in development and faces various challenges before commercialization. The team plans to publish findings once the study concludes.
Read more →NAUTNautilus Biotechnology Launches “First Access Challenge”
SEATTLE, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the launch of the First Access Challenge, a research competition f
Read more →NAUTNautilus Biotechnology Reports Third Quarter 2022 Financial Results SEATTLE, WA
Nautilus Biotechnology Reports Third Quarter 2022 Financial Results SEATTLE, WA, November 1, 2022 - Nautilus Biotechnology, Inc. (NASDAQ NAUT or "Nautilus"), a company pioneering a single molecule proteome analysis platform, today reported financial results for the third quarter
Read more →NAUTNautilus Biotechnology to Announce Third Quarter 2022 Financial Results on November 1, 2022
SEATTLE, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced it will report financial results for the third quarter 2022 before
Read more →NAUTNautilus Biotechnology to Participate in the Capital One Spatial Biology & Proteomics Summit
SEATTLE, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the company will be participating in the upcoming Capital One Spa
Read more →NAUTNautilus Biotechnology Joins Human Proteome Organization (HUPO) Industrial Advisory Board
SEATTLE, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced it has joined the Human Proteome Organization (HUPO) Industrial A
Read more →NAUTNautilus Biotechnology to Participate in the Morgan Stanley Global Healthcare Conference
SEATTLE, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the company will be participating in the upcoming Morgan Stanley G
Read more →NAUTNautilus Biotechnology Reports Second Quarter 2022 Financial Results SEATTLE, WA
Nautilus Biotechnology Reports Second Quarter 2022 Financial Results SEATTLE, WA, August 2, 2022 - Nautilus Biotechnology, Inc. (NASDAQ NAUT or "Nautilus"), a company pioneering a single molecule proteome analysis, today reported financial results for the second quarter ended Ju
Read more →NAUTNautilus Biotechnology Appoints Eric Spence as Vice President of Instrument Engineering and Ken Kuhn, Ph.D., as Vice President of Reagent and Platform Development
SEATTLE, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced further expansion of its management team with the appointments of
Read more →NAUTNautilus Biotechnology to Announce Second Quarter 2022 Financial Results on August 2, 2022
SEATTLE, July 13, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced it will report financial results for the second quarter 2022 befor
Read more →NAUTNautilus Biotechnology Reports First Quarter 2022 Financial Results SEATTLE, WA
Nautilus Biotechnology Reports First Quarter 2022 Financial Results SEATTLE, WA, May 3, 2022 - Nautilus Biotechnology, Inc. (NASDAQ NAUT or "Nautilus"), a company pioneering a single molecule proteome analysis, today reported financial results for the first quarter ended March 3
Read more →NAUTNautilus Biotechnology Appoints Gwen Weld as Chief People Officer and Sheri Wilcox, Ph.D., as Vice President of Affinity Reagent Development
SEATTLE, April 12, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the appointments of Gwen Weld as Chief People Officer and Sheri W
Read more →NAUTNautilus Biotechnology to Announce First Quarter 2022 Financial Results on May 3, 2022
SEATTLE, April 07, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced it will report financial results for the first quarter 2022 befor
Read more →NAUTNautilus Biotechnology to Present at EuPA and AACR Meetings
• Co-founder and Chief Scientist Parag Mallick, Ph.D., to present lecture at Annual Congress of the European Proteomics Association (EuPA) • Associate Director Greg Kapp, Ph.D., to present poster at American Association for Cancer Research (AACR) Annual Meeting SEATTLE, April 0
Read more →NAUTNautilus Biotechnology Appoints Karen Akinsanya, Ph.D., to Board of Directors Schr dinger President of R D, Therapeutics brings extensive leadership in commercializing breakthrough biotechnologies to company developing p
Nautilus Biotechnology Appoints Karen Akinsanya, Ph.D., to Board of Directors Schr dinger President of R D, Therapeutics brings extensive leadership in commercializing breakthrough biotechnologies to company developing platform for comprehensively quantifying the proteome to ena
Read more →NAUTNautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2021 Financial Results SEATTLE, WA
Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2021 Financial Results SEATTLE, WA, February 24, 2022 - Nautilus Biotechnology, Inc. (NASDAQ NAUT or "Nautilus"), a company pioneering a single molecule proteome analysis platform, today reported financial results for
Read more →NAUTNautilus to Participate in the 42nd Annual Cowen Health Care Conference
SEATTLE, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the company will be participating virtually in the upcoming 42nd A
Read more →NAUTNautilus Biotechnology to Announce Fourth Quarter and Full Year 2021 Financial Results on February 24, 2022
SEATTLE, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced it will report financial results for the fourth quarter and full y
Read more →NAUTNautilus and Abcam Announce Strategic Partnership to Accelerate Exploration of the Proteome
SEATTLE and CAMBRIDGE, United Kingdom, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, and Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator
Read more →NAUTNautilus Biotechnology Reports Third Quarter 2021 Financial Results SEATTLE, WA
Nautilus Biotechnology Reports Third Quarter 2021 Financial Results SEATTLE, WA, November 2, 2021 - Nautilus Biotechnology, Inc. (NASDAQ NAUT or "Nautilus"), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today reported financial r
Read more →NAUTNautilus Biotechnology to Announce Third Quarter of Fiscal Year 2021 Financial Results on November 2, 2021
SEATTLE, Oct. 11, 2021 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced it will report financial results for the third quarter of fiscal y
Read more →NAUTNautilus to Participate in the Morgan Stanley Global Healthcare Conference
SEATTLE, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the human proteome, today announced the company will be participating virtually in the upcoming
Read more →NAUTNautilus Biotechnology Reports Second Quarter 2021 Financial Results
SEATTLE, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a life sciences company creating a platform technology for quantifying and unlocking the complexity of the proteome, today reported financial results for the second quarter ende
Read more →NAUTNautilus Biotechnology Appoints Karl Voss, Ph.D., as Vice President of Life Sciences Research and Development
SEATTLE, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the appointment of Karl Voss, Ph.D., as Vice President of Life Sci
Read more →NAUTNautilus Biotechnology to Announce Second Quarter of Fiscal Year 2021 Financial Results on August 10, 2021
SEATTLE, July 13, 2021 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced it will report financial results for the second quarter of fiscal
Read more →NAUTNautilus Biotechnology Appoints Emma Lundberg, Ph.D., to Scientific Advisory Board
SEATTLE, June 17, 2021 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the appointment of Emma Lundberg, Ph.D. to its Scientific Advisory
Read more →NAUTNautilus Biotechnology Debuts as Publicly Traded Company, Seeks to Deliver on the Untapped Potential of the Human Proteome
Business combination transaction with Arya Sciences Acquisition Corp III, a special purpose acquisition company sponsored by Perceptive Advisors, closed on June 9, 2021 Publicly traded company renamed Nautilus Biotechnology, Inc. Common stock commences trading under ticker symb
Read more →NAUTFinancial Information Nautilus Biotechnology, Inc. Unaudited Condensed Financial Statements As of
Financial Information Nautilus Biotechnology, Inc. Unaudited Condensed Financial Statements As of March 31, 2021 and December 31, 2020 and for the Three Months Ended March 31, 2021 and 2020 Page(s) Nautilus Biotechnology, Inc. Unaudited Condensed Financial Statements Conden
Read more →NAUTARYA Sciences Acquisition Corp III Announces Extraordinary General Meeting Teleconference Details NEW YORK, NY, JUNE 1, 2021-ARYA Sciences Acquisition Corp III ("ARYA") (Nasdaq: ARYA), today announced that, due to the pu
ARYA Sciences Acquisition Corp III Announces Extraordinary General Meeting Teleconference Details NEW YORK, NY, JUNE 1, 2021-ARYA Sciences Acquisition Corp III ("ARYA") (Nasdaq: ARYA), today announced that, due to the public health and safety concerns related to the coronavirus
Read more →NAUTFiled by ARYA Sciences Acquisition Corp III Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: ARYA Sciences Acquisition
Filed by ARYA Sciences Acquisition Corp III Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: ARYA Sciences Acquisition Corp III Commission File No. 001-39434 Nautilus Biot
Read more →NAUTNext-Gen Proteomics Company Nautilus Biotechnology to List on Nasdaq Through Merger with Arya Sciences Acquisition Corp III Nautilus Biotechnology has entered into a definitive merger agreement with Arya Sciences Acquisi
Next-Gen Proteomics Company Nautilus Biotechnology to List on Nasdaq Through Merger with Arya Sciences Acquisition Corp III Nautilus Biotechnology has entered into a definitive merger agreement with Arya Sciences Acquisition Corp III (Nasdaq: ARYA). Upon closing, the combined
Read more →NAUTARYA SCIENCES ACQUISITION CORP III Report of Independent Registered Public Accounting Firm F-2 Balance Sheet F-3 Notes to Balance Sheet F-4 Report of Independent Registered Public Accounting Firm To the Shareholders and
ARYA SCIENCES ACQUISITION CORP III Report of Independent Registered Public Accounting Firm F-2 Balance Sheet F-3 Notes to Balance Sheet F-4 Report of Independent Registered Public Accounting Firm To the Shareholders and the Board of Directors of ARYA Sciences Acquisition Corp
Read more →Competitive Position
How NAUT ranks across every disease it competes inCompetitive Position is a premium feature
See how NAUT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial